Optical mapping: pioneering the frontier of preclinical antiarrhythmic drug evaluation Authors: Yangpeng Li, Yuqing Zheng, Ruirui Dong, Miao Lin, Tangting Chen, Jianhong Li, Rui Zhang, Ting Liu, Xiaoqiu Tan, Guoliang Hao, Xianhong Ou Published: 2026 ABSTRACT SummaryOptical mapping has emerged as a unique technique in cardiac electrophysiology since its emergence in the 1970s. By acquiring high spatiotemporal resolution optical datasets using fluorescent dyes, this technique propels the progress of cardiac electrophysiology and the development of antiarrhythmic drug evaluation. This review outlines its application in drug evaluation, including the fundamental principles, major advantages, multiple electrophysiological parameters, and combination with other techniques for predicting proarrhythmic risk and identification of antiarrhythmic drugs. An overview of the drugs tested via the optical mapping method is presented, showcasing its extensive practical utility. This review provides a comprehensive framework for the analysis of arrhythmia mechanisms and drug development using optical mapping. Finally, its limitations and prospects of optical mapping in deciphering the arrhythmogenic mechanism and evaluating antiarrhythmic drugs are discussed, providing references for promoting its clinical translation.Subject areas: medicine, optical imaging, biophysics Introduction Regular initiation and synchronous propagation of electrical pulses in the heart are essential for the maintenance of normal cardiac rhythm; any disturbance in these electrical activities is referred to as arrhythmias.1,2,3,4 Arrhythmias primarily arise in hearts that have experienced structural or pathological remodeling, such as heart failure, myocardial infarction, ischemic reperfusion, and hypertrophic cardiomyopathy.5,6,7 However, they can also manifest in structurally sound hearts, as observed in inherited arrhythmogenic diseases like catecholaminergic polymorphic ventricular tachycardia and long-QT syndrome.8,9,10 Malignant arrhythmias, including ventricular tachycardia and ventricular fibrillation, are estimated to be responsible for nearly half of global sudden cardiac deaths,11,12,13 posing a significant health challenge due to their complexity and our limited understanding of the underlying mechanisms.14,15,16 Even though interventional surgeries, such as implantable cardioverter defibrillators and pacemakers, are effective antiarrhythmic therapies, pharmacological intervention is also an indispensable method.17,18 Furthermore, several drugs have been withdrawn from the market in recent decades due to their cardiotoxic effects, many of which were associated with an increased risk of torsades de pointes.19 These considerations highlight a critical issue regarding the necessity and efficacy of drug evaluation, as well as the imperative for the development of novel antiarrhythmic drugs. Numerous ion channels have been identified and characterized through microelectrode techniques, significantly advancing our comprehension of cardiac electrophysiology and the underlying mechanisms of arrhythmias, while simultaneously accelerating the development of antiarrhythmic drugs.20 However, traditional electrode methodologies necessitate stringent experimental conditions, such as the maintenance of the physiological activity of isolated cardiomyocytes and the meticulous and stable operation on the membrane. These challenges greatly limit the popularity and application of the technique. Additionally, the rapid upstroke and conduction of action potentials (APs) through membrane ion channels occur within milliseconds,21 as a functional syncytium, the electrical excitation and conduction of the heart are holistic and global behaviors, which single-cell electrode techniques fail to adequately address in terms of cell-to-cell connectivity and communication. Furthermore, with the increasing identification of inherited and gene-related arrhythmias in clinics, conventional electrode methods are insufficient to meet the demands for efficient and high-throughput drug evaluation in massive research work. Consequently, there is an urgent need for a technique that offers high efficiency in drug evaluation to address these challenges in the rapid development of cardiac electrophysiology. Since its introduction in the 1970s, optical mapping has become a powerful tool, playing a unique role in the field of cardiac electrophysiology (Efimov et al.).22,23 This technique provides novel perspectives in mechanistic understanding of arrhythmia and meanwhile enhances our comprehension of complex arrhythmia. For arrhythmias cannot be visualized in the heart until Pertsov A. M. et al. elucidated that ventricular fibrillation could be translated into dominant frequency analysis by Fourier analysis and optical mapping method.24 In addition to providing high-throughput datasets with high spatiotemporal resolution for the precise study of complex dynamics, optical mapping possesses a broad sampling area, enabling the recording of optical signals from larger animal models (e.g., sheep and pigs) as opposed to murine or rabbit hearts. Moreover, the optical mapping system can be applied across multiple scales, including isolated hearts, cardiac wedges and slices, and cardiomyocyte monolayers, allowing simultaneous recording of transmembrane voltage and intracellular calcium signals (J. Jalife).25 Furthermore, the integration of optical mapping with optogenetics is paving the way for the clinical application of implantable optical pacemakers, pain-free and cell-selective defibrillation.26,27 Currently, this technology has become one of the most significant tools for investigating the mechanisms of cardiovascular diseases and drug evaluation. It enables consecutive imaging of macroscopic electrical propagation and calcium dynamics of the heart preparations under both physiological and pathological conditions, particularly in the context of drug interventions. This capability offers valuable insights into the mechanistic aspects of cardiac electrophysiology and the evaluation of antiarrhythmic medications.1,2,22,28 Consequently, it is imperative to comprehend the current application of this technology in drug evaluation. In this review, we outline the fundamental principles of optical mapping and its advantages, as well as the multi-parameter analysis of arrhythmia mechanisms during the assessment of antiarrhythmic drugs across various scales. We also summarize and discuss the drugs that have been evaluated using optical mapping, alongside the prevailing challenges and future directions in this field. Basic principles and major advantages of optical mapping The detailed description of the optical mapping system, including its working principles and the properties of optical dyes, has been thoroughly discussed in previous literatures.22,25 The following section provides a general overview of the optical mapping methodology and highlights the advantages of this approach in comparison to other electrode-based techniques. Working principle of optical mapping The working principle of optical mapping is illustrated in Figure 1. Following the successful loading of optical probes (e.g., voltage-sensitive dye and intracellular calcium indicator) into cardiac preparations, excitation lights (mainly light emitting diodes) are utilized to activate the fluorescent probes. The emitted light is subsequently collected using lenses and is then filtered and split based on its intrinsic emission wavelength through custom-designed filter systems. High-speed cameras, typically electron-multiplying charge-coupled device (EMCCD) or complementary metal-oxide semiconductor (CMOS) cameras, were utilized to capture the optical signals associated with APs and intracellular calcium transients (CaTs).1,22,29 The raw high-throughput optical datasets are subsequently processed and analyzed using specialized software, enabling the study of excitation generation and electrical conduction, and calcium dynamics. This analysis aims to elucidate the underlying mechanisms of arrhythmogenesis or antiarrhythmic effects in the context of potential antiarrhythmic drug interventions.23,30 Working principle of cardiac optical mapping Images on the left section illustrate the simplified principles of optical mapping. Images on the upper right section present a typical setup of the optical mapping system, which commonly employs EMCCD or CMOS cameras in conjunction with optical filters. Images on the lower right section show the detailed working principles of optical dyes and supplementary devices employed in cardiac optical mapping experiments. The voltage-sensitive dye interacts with charged proteins located within the cell membrane; upon excitation by specific light wavelengths, the resulting emission light is captured by detectors. Bandpass filters are utilized to isolate the specific spectral bands associated with the optical dyes. Additionally, essential auxiliary devices such as a water bath, heating control system, peristaltic pump, ECG amplifier, and stimulators are incorporated into the experimental setup. ECG, electrocardiogram; EMCCD, electron-multiplying charge-coupled device; CMOS, complementary metal-oxide-semiconductor. Advantages of optical mapping Optical mapping offers several advantages over traditional electrode techniques in the study of electrophysiological phenomena (Figure 2). Firstly, it enables the acquisition of high-throughput datasets with high spatiotemporal resolution. This is achieved through the integration of sensitive fluorescent probes and high-speed cameras,1 which facilitate the collection of extensive electrophysiological data at sampling rates of up to 10,000 Hz and pixel sizes of less than 32 μm. Such capabilities allow for precise identification of electrical excitation and propagation patterns.1 Secondly, optical mapping encompasses a significantly larger sampling area, exceeding 10,000 pixels, which surpasses the limited recording areas associated with conventional electrode techniques, such as multielectrode array (MEA) and patch clamp.27,31 This expansive sampling area permits imaging of larger animal hearts, as opposed to solely murine models.1,2,32,33 Thirdly, optical mapping allows for the simultaneous measurement of membrane voltage and intracellular calcium signals. By utilizing excitation light at a wavelength compatible with both voltage and calcium-sensitive dyes (e.g., RH237 and Rhod-2 AM, common optical dyes are summarized in Table 1), researchers can capture these signals concurrently. This capability enables the analysis of multiple electrophysiological parameters, including AP duration (APD), CaT duration (CaTD), conduction velocity (CV), time constant (τ), time to peak, and dominant frequency. Importantly, these simultaneously recorded signals facilitate a comprehensive investigation of the coupling relationship between voltage and calcium, which is essential for understanding the arrhythmogenic interactions between these two signals and may provide insights into excitation-contraction coupling.34,35 Fourthly, optical mapping provides a dynamic and macroscopic perspective on arrhythmogenesis, allowing for the recording and analysis of abnormalities in the overall behavior of electrical pulses, including irregular initiation and propagation during arrhythmias. Its visualization capabilities are particularly beneficial for studying complex and chaotic electrophysiological irregularities, capturing millisecond-level variations such as after depolarizations, ectopic beats, reentry, and spatial discordant alternans.36,37 Lastly, optical mapping minimizes damage to living preparations and preserves undistorted signals. Advances in solutions and instrumentation have enhanced the preservation of physiological activity and contraction in carefully isolated hearts, tissues, and cardiomyocytes, enabling the recording of their intrinsic properties (Figure 3). Additionally, the use of optogenetic markers in specifically excitable cardiomyocytes (e.g., the HCN4 marker for the cardiac conduction system) allows for wireless and pain-free pacing, as well as the assessment of the electrophysiological properties of targeted cells, which might contribute to precision medicine.38,39 Furthermore, optical signals remain unaffected by electromagnetic fields, ensuring the acquisition of high-fidelity datasets.1,2,40 In summary, optical mapping presents several advantages over conventional electrode techniques, including high spatiotemporal resolution, extensive sampling areas, simultaneous recording of voltage and calcium signals, comprehensive understanding of arrhythmogenesis, and the preservation of undistorted signals with minimal impact on living preparations. Advantages of cardiac optical mapping Optical mapping experiments are performed under physiological conditions to maintain the physiological activity of cardiac preparations. Massive datasets of optical signals with high spatiotemporal resolutions are captured by high-speed cameras. Meanwhile, it facilitates the simultaneous recording of voltage and calcium signals, thereby accommodating the requirements for large-scale heart imaging, such as sheep. Macroscopic and integrative behaviors, such as AP conduction, can be visualized and analyzed by producing conduction heat maps. Optical mapping experiments can be applied to a range of heart preparations, from monolayer cultures to living animal models. Table 1Properties of common optical dyesNameTypeExcitation,Emission lightResponse speedCardiac riskAdvantageDisadvantageDi-4-ANEPPSVmEx 460–530Em 600–700psHighFast responseLow costINa inhibition,PhototoxicityDi-8-ANEPPSVmEx 470–540Em 610–720psMediumStable signalPhototoxicityDi-4-NBDQBSVmEx 660Em >700psLowHigh penetration depth (1–4 mm)Expensive,Excitation by red lightFluoVoltVmEx 488Em 520–560psLowStable signalAnti-photobleachingExpensive,Require high-speed cameraRH237VmEx 530–550Em 650–700psMediumSuitable for simultaneous dye loading (Rhod-2)Require E-C uncoupler BlebbistatinFura-2Ca2+Ex 340 / 380Em 510msLowRatio-dependentRequire double excitation,PhototoxicityRhod-2AMCa2+Ex 550Em 580msMediumGood compatibility with Vm dyeMitochondria-targetPhotobleachingFluo-4Ca2+Ex 494Em 516msLowHigh sensitivity,High brightnessPhotobleaching Properties of common optical dyes Multiple scales in optical mapping and optogenetics Optical mapping experiments can be performed on various cardiac preparations, including whole isolated hearts, cardiac slices, cardiac wedges, cardiac monolayers, cardiac organoids, and in vivo hearts. Advances in camera technology and computational simulation have enabled the implementation of panoramic optical mapping. Furthermore, optical mapping can be combined with optogenetic techniques to facilitate optical pacing and defibrillation. Electrophysiological parameters in the mechanistic understanding of arrhythmia Electrophysiological parameters are essential for understanding cardiac electrophysiology and the mechanisms underlying arrhythmias. Detailed interpretation of these parameters derived from optical mapping experiments during pharmacological assessments can further clarify the antiarrhythmic mechanisms of the potential antiarrhythmic drugs. Basic electrophysiological parameters of optical mapping mainly include APD, CV, CaTD, CaT alternans, CaT amplitude, tau of decay (τ), time to peak, dominant frequency, and the coupling relationship between voltage and calcium (latency). Additionally, other arrhythmogenic patterns, including afterdepolarization, ectopy, reentry, phase singularity, and imbalance of intracellular calcium homeostasis, significantly contribute to the mechanistic understanding of antiarrhythmic drugs. Of note, software tools play a key role in optical mapping datasets based on various algorithms. ElectroMap,30 OmapScope 5, Matlab-based RHYTHM,41 and KairoSight42 are common optical mapping analysis software tools. Raw optical signals are mostly filtered by spatial and temporal method, thereby generating various filter patterns, such as Gauss filter, zero-phase filter, median filter. etc. Generation of conduction maps is based on isochronal mapping and activation time according to Efimov. Reentrant circuit analysis mainly based on phase mapping, it can help to locate phase singularity when reentrant arrhythmias occur. The AP is generated by the coordinated activity of multiple ion channels, which work in concerts to sustain normal cardiac rhythm and contraction. Even minor changes or dysfunctions in a single ion channel may lead to severe cardiac arrhythmia.43,44,45,46,47,48 Notably, pronounced variations in APD and APD dispersion (Figure 4A) can interrupt cardiac conduction at the junctions of regions exhibiting significant differences, potentially triggering abnormal electrophysiological activities. Intervention with antiarrhythmic drugs may alleviate steep APD variations, thereby decreasing the incidence of arrhythmias. Recent research has indicated that progesterone reduced the incidence of ventricular arrhythmias by attenuating APD dispersion.49 Major electrophysiological parameters in drug evaluation (A) Drug intervention may alleviate the prolongation of APD and CaTD. (B) The coupling relationship of AP and CaT was defined as latency. The latency is classified as peak, midpoint, and decay latency. (C) CV analysis under drug intervention. (D) Calcium spatial discordant alternans in calcium homeostasis analysis. (E) Reentrant circuits are suppressed by antiarrhythmic drugs. AP, action potential; APD, action potential duration; APD80, APD at 80% recovery; CaT, calcium transient; CaTD, CaT duration; CaTD80, CaTD at 80% recovery. Proteins and channels regulating calcium release and reuptake from the sarcoplasmic reticulum are pivotal in maintaining calcium homeostasis and regulating heart contraction. Dysfunction of these proteins may disrupt the balance of calcium cycling, leading to delayed afterdepolarizations. Alterations in CaTD (Figure 4A) and Ca2+ oscillation signify impaired calcium homeostasis, while CaT alternans are considered precursors to reentrant arrhythmias. An antiarrhythmic study revealed that prolonged CaTD80 (CaTD at 80% recovery) correlated with an increased incidence of arrhythmias in a mouse model of myocardial infarction; treatment with allopurinol alleviated the prolongation of CaTD80 and reduced the occurrence of ventricular arrhythmias.50 Upon the transmission of the AP to the cardiomyocyte membrane, the ICaL (L-type calcium current) is activated after a brief delay, leading to the activation of ryanodine receptor 2 (RyR2) and a substantial release of calcium from the sarcoplasmic reticulum. This coupling process of AP and CaT is defined as latency (Figure 4B), which is crucial for studying calcium-induced arrhythmias and the mechanisms of excitation-contraction coupling.34,35 Under physiological conditions, AP is harmoniously synchronized with CaT through the intricate coordination of various ion channels; however, pathological stress may interrupt this balance, resulting in uncontrolled electrical abnormalities. Several studies have indicated that impaired coupling between Vm (membrane potential) and Ca2+ increases the incidence of arrhythmias,51,52 and interventions such as dexmedetomidine have been shown to restore the compromised Vm-Ca2+ latency, thereby preventing ventricular arrhythmias.52 CV is closely associated with the excitability of membranes, the depolarization upstroke of cardiomyocytes, and the cardiac conduction system. Nav1.5 and connexin Cx43 (connexin43) are mainly in charge of electrical conduction. Pathological conditions can induce electrophysiological remodeling that alters the expression of these proteins, resulting in a reduction of CV and subsequent conduction delays and deviations (Figure 4C). Research has demonstrated that pathological changes or genetic mutation can upregulate the expression of Nav1.5 and Cx43, which in turn decreases CV and induce reentrant circuits.53,54 Pharmacological interventions targeting Nav1.5 and Cx43 have the potential to attenuate conduction abnormalities and prevent reentrant arrhythmias. The maintenance of calcium homeostasis in cardiomyocytes includes regulalrelease and uptake of calcium. Once the balance is broken, abnormal calcium handlingmay interrupt normal heart rhythm and generate calcium-induced arrhythmias, such asspatial discordant alternans (Figure 4D). The relevant molecular and ionic mechanisms are generally based on changed expression and dysfunction of calcium handling proteins. Arrhythmogenic mechanisms are generally categorized into two types: (1) enhanced excitation or abnormal initiation of electrical impulses, and (2) conduction abnormalities, with ectopy and reentry (Figure 4E) serving as notable examples of these types.55 Phase singularity is widely accepted as the organizing center of the spiral waves or the initiation of wavebreak.56 Understanding the formation and movement of phase singularity aids in characterizing arrhythmia dynamics.37,57 Optical mapping studies of murine hearts with the phospholamban (PLN)14 del mutation suggested that the deletion of PLN14 resulted in conduction block and wave break, leading to the emergence of the formation of a phase singularity. As the phase singularity moved, the reentry started, and ventricular tachycardia was maintained. Antiarrhythmic drug evaluation in optical mapping Characteristics of potential antiarrhythmic drugs evaluated using optical mapping In this study, we conducted a comprehensive analysis of 90 pharmacological agents utilized in the evaluation of antiarrhythmic properties through optical mapping. Table 2 presents a detailed list of the 90 drugs/chemicals. The corresponding literature selection strategy was illustrated in Figure 5. This analysis includes a brief classification and scoring based on the distinct electrophysiological effects of these agents, alongside a summary of their global prevalance. It has been observed that the adoption of this technology for drug evaluation has steadily increased since 2002, with a notable rise in post-2010 (Figure 6A). The United States, China, and Japan have emerged as the leading contributors to this work (Figure 6B). These 90 drugs were categorized into four aspects by their electrophysiological effects: stabilization of membrane potential, maintenance of intracellular calcium homeostasis, conduction preservation, and amelioration of electrical storm (Figure 6C). The stabilization of membrane potential is the basis for maintaining the normal cardiac excitability and conduction. Disruptions in APD or regional APD heterogeneity could serve as a potential substrate for lethal arrhythmias.58,59,60 Optical mapping can detect APD and its spatial heterogeneity to evaluate the potential antiarrhythmic effects of drugs (Figure 6D, Function 1). Table 2Score and classify the potential antiarrhythmic drugs based on their electrophysiological functionsDrug/ChemicalsTransmembrane voltage stabilizationCalcium homeostasis maintenanceConduction preservationElectrical storm suppressionScoreApamin111114Dapagliflozin11114Dexmedetomidine11114Empagliflozin11114Propranolol11114Ranolazine11114Valsartan/sacubitril11114Anakinra11103Apelin10113Azumolene11013Ba2+11103Dantrolene11103GS96711103Insulin11103JB2019A11103KN9311103Mannitol11103Melatonin11103Mitomycin-C10113Nicorandil11103Naringenin11103Pilsicainide10113Quinidine10113Relaxin10113Resveratrol11103Rotigaptide10113Rosuvastatin01113Acetylcholine10102AICAR11002BAPTA-AM01012Bepridil10012D, l-Sotalol10012DPO-110012Elsholtzia ciliata10102EN46001102Enalapril00112Ginsenoside Rb101102Glibenclamide10012GSK219387411002Hemoglobin10012HMR109800112Nifedipine01012NS30910102Resolvin-D110102R-propafenone11002Sophoridine10102SP60012500112Vericiguat01012VK-II-3601012YXDJ01012Allopurinol01001Amiodarone00101Anti-IL-601001AZD053001001CaMKII 281/282V00101cANF00101Cisapride10001Cromakalim00011CryAB10001Elsholtzia00011Epsilon10001Flecainide10001Flunarizine10001Flurandrenolide10001GS-6201-1w00101Hydroxychloroquine00101Ivabradine00101Levosimendan01001Lidocaine10001Mirabegron00011Nicotine00101Nifekalant00011N-palmitoyl glycine00101NPR-B01001Pinacidil01001PITX210001Pirfenidone00101Pravastatin01011Progesterone01001RPR26024301001Ru36001001RXP-E00101SGK1-Inh10001Spexin00101Theophylline00101Ursodeoxycholic acid00101Verapamil00011VU040560110001w700101293B10001 Score and classify the potential antiarrhythmic drugs based on their electrophysiological functions Criterion of literature selection All the references were derived from PubMed between 2001 and 2025. To avoid missing important information, the keywords was set as “optical mapping” and “cardiac”, and 2,125 results were found. Then the studies were scanned to evaluate whether drug testing was involved. Once drugs or other potential agents were observed, we would thoroughly study the entire article to figure out whether the drug was antiarrhythmic, proarrhythmic, or ineffective. After that, specific electrophysiological parameters of these drugs were evaluated, including AP, calcium handling, conduction, and arrhythmia incidence. AP can be further studied in duration and heterogeneity, APD alternans or SDA was also evaluated, then abnormality in AP repolarization like EAD or DAD were investigated. Once one parameter was positively changed by the drug and the drug was defined as antiarrhythmic, then it could earn 1 point (even though the drug can have two or more effects). The rest three parameters were evaluated the same way. APD, action potential; ALT, alternans. SDAs, spatial discordant alternans; EAD, early afterdepolarization; DAD, delayed afterdepolarization. CaTD, calcium transient duration; ScaE, spontaneous calcium elevation; DF, dominant frequency; PS, phase singularity. Antiarrhythmic effect and a summary of potential antiarrhythmic drugs evaluated by optical mapping method (A) Optical mapping studies in antiarrhythmic drugs are gradually increasing each year. (B) National distribution of antiarrhythmic drug publications using optical mapping. (C) Four key electrophysiological functions are demonstrated using optical mapping, including membrane potential stabilization, calcium homeostasis maintenance, conduction preservation, and electrical storm suppression. (D) According to their electrophysiological functions, potential antiarrhythmic drugs were roughly classified and illustrated using a Venn diagram. Furthermore, instability in intracellular calcium levels plays a critical role in calcium-induced arrhythmias.61 Physiological activation or altered expression of calcium channels may lead to intracellular calcium overload, which can precipitate delayed afterdepolarizations or more severe cardiac events, including triggered activities and reentrant ventricular arrhythmias.61,62,63 The impact of pharmacological agents on calcium homeostasis can be assessed through the examination of various indicators, including CaT, calcium kinetic parameters, and calcium alternans, as derived from optical mapping data (Figure 6D, Function 2). Additionally, conduction delays or deviation can result in local conduction blocks, leading to rapid transformation of reentry circuits. Irregular and spatially discordant depolarization and repolarization are critical contributors to arrhythmogenic events. Local heterogeneity of APD or CaTD may lead to asynchronous depolarization or repolarization, often accompanied by wave break and reentry phenomena. Optical mapping serves as a valuable tool for assessing the potential antiarrhythmic properties of pharmacological agents through the examination of CV and reentry phenomena (Figure 6D, Functions 3 and 4). Certain potential antiarrhythmic agents exhibit singular effects on cardiac electrophysiology, whereas others demonstrate multifunctional properties Examples of the latter include apamin, dapagliflozin, dexmedetomidine, empagliflozin, propranolol, ranolazine, and valsartan/sacubitril, each of which can achieve a maximum score of 4 points (Table 2). Notably, a significant proportion of these drugs are not primarily recognized for their cardiovascular or antiarrhythmic properties; rather, many are employed in the treatment of various non-cardiovascular conditions. This observation suggests that numerous potential antiarrhythmic agents have been identified and assessed through optical mapping methodology. Cardiovascular disease models at multiple scales in drug evaluation by optical mapping Cardiovascular disease models have been extensively employed in drug evaluation within optical mapping studies, mainly including ischemic heart disease models (such as myocardial infarction and myocardial ischemia-reperfusion),64,65,66 heart failure,65,67,68,69 inherited proarrhythmic cardiomyopathies (notably catecholaminergic polymorphic ventricular tachycardia),37,51,52,70 and drug-induced arrhythmic models.71 The left ventricle, innervated by the left anterior descending artery, is frequently the site affected by ischemic heart disease. Optical mapping enables simultaneous assessment of electrophysiological differences between ischemic and non-ischemic regions, facilitating the evaluation of potential pharmacological interventions and the identification of antiarrhythmic drug efficacy in ischemic heart conditions.66 Similarly, pharmacological agents can be tested for their therapeutic potential in chronic heart failure and inherited proarrhythmic cardiomyopathies to prevent arrhythmias.69,72 Importantly, these disease models can be investigated across multiple experimental scales, including isolated whole hearts,66 cardiac tissue slices,29 and cellular monolayers.72 (Figure 3). Technical comparison and applicable selection Optical mapping can be applied in various occasions while conventional electrophysiological techniques are restricted based on multiple factors. For instance, in Vm evaluation, the spatial resolution with micrometer level and millisecond time resolution of optical mapping can capture calcium wave propagation anomalies that MEA cannot detect, in the ex vivo heart model, panoramic imaging system can visualize the conduction of electrical signals throughout the heart, providing intuitive evidence for the study of arrhythmogenesis. However, in the screening of conventional drug concentration effect relationships, optical mapping and MEA have consistency in detecting macroscopic parameters such as APD. In this case, the high-resolution advantage of optical mapping is not necessary, and technical solutions can be selected based on experimental costs and flux requirements. In brief, the selection of optical mapping methods (e.g., isolated whole heart, cardiac slices, etc.) or other methods are based on specific experimental objectives. Optical mapping combined with other techniques for discovering ionic and molecular mechanisms of antiarrhythmic drugs The advancement of cardiac electrophysiology research has been markedly propelled by the application of optical mapping, which has elucidated both traditional and novel electrical and dynamic mechanisms underlying arrhythmias.37 However, these mechanisms only represent critical phenotypic features, such as spatial APD heterogeneity, visualized spiral wave, conduction block, and calcium dyshomeostasis. These phenotypes cannot provide deeper understanding of the molecular pathways driving arrhythmogenesis, thereby obscuring potential therapeutic targets. Nevertheless, integration of established traditional methodologies with optical mapping such as patch clamp, western blotting, and immunofluorescence enables a more comprehensive elucidation of molecular and ionic mechanisms (Figure 7), as well as identification of potential therapeutic targets.73,74,75 Patch clamp can help to verify optical mapping results and realize deeper mechanism searching in three aspects. Firstly, patch clamp can help to validate conduction abnormalities in optical mapping recordings, and Nav 1.5 would be the preferential testing target.37,76,77 Meanwhile, when AP was found changed by optical mapping (duration or spatial heterogeneity), patch clamp can help to precisely locate repolarization potassium channels in specific regions (e.g., atrial or ventricular myocytes).74,78 For optical datasets of calcium homeostasis, patch clamp can help to target calcium release or recycling channels like RyR2, Ca2+ ATPase (SERCA), and PLN.76 Immunofluorescence techniques can additionally realize spatial localization of key factors involved in excitation and conduction processes, which manifests as changed CV quantification or conduction deviation characterized by optical mapping.79 For the above targets associated with abnormal ion handling, western blot can help to quantify the expression of the potential therapeutic target underling the optical mapping phenotypes. The crucial role that computational simulation plays with optical mapping can be summarized as “observation to interpretation and prediction.” It can contribute to revert and interprate optical mapping datasets to computable biophysical parameters such as ion current imbalance, downregulation of linker protein expression, and increased tissue heterogeneity (Thomas O’Hara et al.). Also, it can simulate multi-scale myocardial electrophysiological models for reverse optimization of model parameters. For instance, adjusting RyR2 leakage rate or SERCA activity, the simulated CaT decay curve can be matched with experimental data. Moreover, pathological perturbations in disease models (such as 20% decrease in sodium channel expression and a 30% increase in fibrosis area) can predict the threshold for reentry formation and trigger activity probability, thereby identifying high-risk arrhythmia states and drug intervention in advance.80,81,82,83 Optical mapping combined with multiple techniques. Optical mapping is often combined with other techniques to evaluate antiarrhythmic drugs Conventional techniques can help to explore molecular and ionic mechanisms of arrhythmia, including patch clamp, MEA, western blotting, and immunofluorescence. While emerging technologies can significantly improve the detection efficiency of antiarrhythmic drugs, and they can meanwhile contribute to the development of precision medicine and personalized treatment, such as optogenetics, machine learning, computer simulation, and artificial intelligence. By integration with computational approaches, optical mapping can realize multi-scale modeling and simulation verification; researches can make accurate prediction of changed electrophysiological parameters induced by pharmacological intervention, such as 3D reconstruction of whole heart repolarization dispersion in cardiac slice imaging. Computational models can also help to optimize experimental designation and optical mapping methodologies. By simulating drug effects in different concentrations and targets, the optimal experimental parameters are determined to reduce experimental bias and improve research accuracy. Machine learning is another new technique applied in optical mapping studies; it can help to automatically recognize the formation or the source of arrhythmias under potential antiarrhythmic drug therapy, which may significantly fasten drug screening efficacy. Meanwhile, machine learning excels at extracting implicit pathological features from these high-dimensional data, surpassing the limitations of traditional manual measurements or analysis. Moreover, it can establish ion channel dynamics from observed optical signals, which greatly enhances parameters estimation based on multi-scale interaction. For instance, single ion channel function can be deduced by optical mapping datasets under the intervention of machine learning. Besides, machine learning can automatically analyze high through-put optical datasets to accomplish abnormal electrical conduction patterns. Discussion Optical mapping has significantly advanced the field of cardiac electrophysiology by facilitating high-resolution, simultaneous recording of transmembrane voltage and intracellular calcium dynamics. This technique has elucidated complex arrhythmogenic substrates, such as spatially heterogeneous APD and calcium alternans, which are challenging to be explored using traditional micro-electrode arrays. As a result, optical mapping has emerged as a robust platform for preclinical assessment of antiarrhythmic agents, effectively bridging macroscopic electrophysiological phenotypes with underlying microscopic ion channel or protein abnormalities. However, several limitations persist in cardiac optical mapping methodologies. A primary concern involves the use of fluorescent dyes, as photobleaching remains an inherent and frequently reported issue that can compromise data integrity. The selection of inappropriate fluorescent dyes may yield distorted signals and lead to erroneous interpretations. Additionally, the absence of neuro-humoral regulation in ex vivo optical mapping studies remained controversial. In vivo optical mapping presents further challenges, including dye-induced cardiotoxicity and the requirement for excitation-contraction uncouplers, both of which may disrupt the physiological function of cardiac tissues and potentially undermine the accuracy of pharmacological evaluations. Fluorescent dyes and excitation-contraction uncoupler Lipophilic voltage-sensitive dyes are generally potentiometric and small-molecule synthetic indicators that associate with membrane proteins and exhibit periodic fluctuations in fluorescence intensity in response to changes in membrane potential under excitation light. These dyes exhibit extremely rapid response times. However, their utility is constrained by photobleaching, which significantly limits experimental duration, and phototoxicity, which may induce aberrations in cardiac physiological function. Intracellular calcium indicators usually enter cardiomyocytes facilitated by surfactants such as Pluronic F127; nevertheless, the surfactant itself can disrupt the native structural integrity of the cardiomyocyte membrane. Additionally, dual-dye imaging necessitates the use of dyes with minimal spectral overlap to prevent signal interference. For example, RH237 (emission peak at 782 nm) and Rhod-2 AM (emission peak at 578 nm) commonly employed fluorescent dyes in cardiac optical mapping studies, both excited at 530 nm (Table 1). Of note, perfusion with these optical dyes may contribute to cardiac side effects.84 As for light penetration, it is important to note that fluorescence signals (emission lights) can only be detected up to a depth of approximately 2 mm from the heart tissue surface, posing challenges for accurately localizing the origins of arrhythmias.1 For uncoupling of excitation-contraction to acquire optical datasets with high fidelity, Blebbistatin is mostly used in optical mapping studies; it can stop the heart beat and help to avoid motion artifacts by inhibition of specific non myosin II ATPase. However, some studies indicate that Blebbistatin has the potential of causing side effects on cardiac electrophysiology,85 while it is still the most widely due to it is the only available myosin 2-specific inhibitor.86 To avoid photobleaching, optical mapping without dye is introduce to cardiac electrophysiological studies. It can capture images with high spatial and temporal resolution without exogenous dye. Since no dye or uncoupler is included in the experiment, photobleaching and cardiac toxicity are avoided, and the real effect of antiarrhythmic drugs can be fully explored. However, without the intervention of dyes or excitation-contraction uncoupler, the signal quality would be greatly damaged because of low signal/noise ratio and motion artifact. Imaging system Typically, imaging systems in this domain comprise high-speed cameras coupled with optical filters. EMCCD and CMOS cameras are mostly applied in the optical mapping field. However, CMOS cameras are increasingly favored due to their lower power consumption and superior imaging performance, particularly in terms of higher sampling rates and enhanced single-pixel resolution. Admittedly, high spatial and temporal resolution fastens the access of high through-put dataset, while there are also several limitations. On the one hand, small tissue such as mice atria imaging is relatively arduous for restricted spatial resolution, and thus causing limited pixel information. Also, there is a potential risk of signal distortion when detecting electrophysiology of subcellular scale like calcium spark. Meanwhile, limited by the response kinetics of fluorescent dyes (such as microsecond level delay of di-4-ANEPPS) and phototoxicity constraints, the actual sampling may be suppressed to 1–2 kHz, making it difficult to accurately analyze the transient electrical reconstruction process in high-frequency arrhythmias (such as ventricular fibrillation). Over the past several decades, optical mapping studies have primarily focused on isolated whole hearts. Nonetheless, planar imaging using a single camera inherently introduces imaging distortions, which impede advancements in cardiac electrophysiology and the planar imaging using a single camera inherently introduces imaging distortions, which impede advancements in cardiac electrophysiology and the mechanistic understanding of arrhythmias. Consequently, panoramic optical mapping has emerged as a complementary technique to address the limitations and information loss associated with two-dimensional imaging.87 It possesses several advantages over 2D mapping systems. Firstly, this approach facilitates the precise localization of abnormal arrhythmogenic sources and propagation patterns. Besides, 3D mapping supports real-time imaging to achieve higher diagnosis efficiency when arrhythmia occurs. Moreover, by the combination of computer reconstruction method, 3D mapping can generate electrophysiological parameters simultaneously in complex arrhythmias, such as atrial fibrillation with heart failure. Further investigation in artificial intelligence and optimization of 3D reconstruction may drive 3D mapping as key technique in the next generation. Despite these advantages, challenges related to imaging of the deep myocardium and issues arising from tissue curvature remain areas requiring further investigation.1,2 Multiple scales in evaluation antiarrhythmic drugs in different animal species Optical mapping is now mainly conducted in four scales, including in vivo, ex vivo, isolated cardiac tissue/slice and even single cell. The option of these models can vary based on specific research objectives and designation. In vivo optical mapping is thought have a promising future due to its lowest harm to the heart. Besides, complete neurohumoral regulation, hemodynamics, metabolic environment, and autonomic nervous system feedback allows for physiological evaluation of proarrhythmic or antiarrhythmic drugs. The present limitations mainly focus on low signal/noise signals and high cost, which hinders its preclinical application. For ex vivo imaging, isolated heart optical mapping is thought to be the most popular method for several factors, drug intervention can be easily realized by the perfusion solution, and hence direct electrophysiological effect could be observed. Besides, it enables high quality imaging with intact heart with physiological activity. Moreover, the low cost and simple operation procedure is also an important factor. However, isolated heart mapping cannot reflect the communication with other system since the neurohumoral regulation has been removed. Cardiac slice or specific tissue (e.g., sinoatrial node) are especially suitable for studying localized function or transverse heterogeneities, while the precise operation and the maintenance of physiological activity may result in unsatisfactory results. Single cell optical mapping is mainly designed to conduct high-throughput pharmacological tests with personalize purpose, while it is rarely used in the present studies, for reentrant circuits and cell-to-cell electrical conduction cannot be realized, which goes against the original intention of optical mapping. In summary, isolated whole heart is now the first choice in optical mapping studies, while the other method can also be applied when achieving specific experimental purpose. For animal option in optical mapping studies, mice, rat, and rabbit hearts appear to be the best choices. Mouse hearts were mainly used in gene related studies and high-throughput drug screening, such as inherited diseases CPVT or LQT, moreover, experimental cost can be saved due to low consumption of optical dyes. Rat hearts are large and are rather suitable for safety evaluation of drugs development, conduction patterns and complex arrhythmias like atrial or ventricular fibrillation can be thoroughly studied. In terms of antiarrhythmic drug evaluation, rabbits are thought to be the first choice, because rabbit hearts possess stronger L-type current than murine hearts, which is especially crucial in repolarization phase 2. However, each animal has its own limitations in optical mapping studies. Mice heart is relatively small and conduction abnormalities or reentrant circuit studies would be limited. Besides, drug metabolic efficiency of murine hearts is faster than humans, thereby hindering the precision of drug evaluation. While rats and rabbits lack the operability of gene editing as mice, and they would also increase of experimental cost on dyes because of the large heart volume. For some top laboratories, larger hearts like dog, sheep, pig, and even shark are conducted to optical mapping studies. Critical challenges in antiarrhythmic drug discovery The critical challenges in antiarrhythmic drug screening can be elucidated in three aspects: the complex of arrhythmias with various targets, the challenge in prediction of proarrhythmic risk, and the lack of personalized therapy. Firstly, the previous key points of antiarrhythmic drug screening were mainly based on ion channels exploration, this greatly restricts the antiarrhythmic drug development and can no longer meet the needs for high-throughput drug screening due to rapid advancement of scientific technologies and accumulating drugs being discovered, as well as the complexity of arrhythmias (most arrhythmias are mediated by various targets). Optical mapping can produce high spatial and temporal datasets with convincing fidelity, and numerous drugs can be explored based on multi-scale exploration with various disease model. Meanwhile, by proper combination of computational simulation, optical mapping can reversely optimize pharmacological parameters to predict the proarrhythmic risk in changed pathological conditions. For instance, by simulating the effect of drugs on CaT decay curves, high-risk patients can be identified and introduced to preclinical drug screening. Multi-model experimental design can be accomplished by optical mapping method, including in vivo, ex vivo and virtual heart imaging. Optical mapping can realize real-time recordings of spiral waves under intervention of various antiarrhythmic drugs and thus provide therapeutic suggestions for personalized treatment. With these optimizations, optical mapping can adapt to the current rapid changes in drug researches. Clinical correlation and optogenetics in precision medicine Clinical diagnosis of arrhythmia includes non-invasive and invasive tests, such as 12-lead ECG, ‌Holter monitoring, wearable devices, and even invasive electrophysiological catheter mapping. These methods cannot capture small conduction block region because of restricted spatial temporal, nor they can explain the potential proarrhythmic mechanism mediated by Vm or calcium handling. Once limitations are overcome in future technology and methodology development, optical mapping can realize timely and accurate arrhythmia detection. Meanwhile, recent human heart obtained from cardiac surgery tested by optical mapping revealed that PVC incidence and other proarrhythmic substrates were significantly attenuated by dantrolene,88 providing objective and direct evidence for clinical antiarrhythmic therapy. Moreover, the electrophysiological phenotype and effects discovered in basic pharmaceutical research can be compared with the efficacy of medication in clinical patients, which may serve as a bridge connecting preclinical evaluation and clinical translation. Optogenetics is recognized as a non-invasive approach characterized by exceptional precision, enabling high spatiotemporal control by single-cell excitation within milliseconds—in targeted cell populations.27 It can help to precisely create disease model and realize arrhythmia induction. Optical mapping of APs and calcium handling can be quantified to integrate the excitation of specific cell type and macroscopic arrhythmia phenotype. Meanwhile, by establishing the disease model propelled by optical control, the potential effect of antiarrhythmic drugs can be precisely detected, for different cell type may react differently to drugs. Besides, gene modification of optical control in non-cardiomyocytes can help to explore the proarrhythmic and antiarrhythmic mechanism, such as fibroblasts. These advantages impel optogenetics a potential part of precision medicine and individualized treatment of arrhythmia in future clinical medicine. Future prospect Optical mapping offers distinctive insights into the mechanistic understanding of cardiac electrophysiology and the development of antiarrhythmic therapeutics. The utilization of dyes exhibiting superior biocompatibility, coupled with advancements in imaging technology, is anticipated to enhance the identification of novel antiarrhythmic agents. There is an emerging trend toward the incorporation of traditional Chinese medicine and non-cardiovascular pharmaceuticals in preclinical cardiac electrophysiological evaluations (Table 2), thereby broadening the spectrum of potential antiarrhythmic drugs. Additionally, innovative surgical materials are being developed and employed in cardiovascular interventions, their biocompatibility and possible cardiac side effects can be effectively assessed through optical mapping techniques. Of note, antiarrhythmic drugs can be therapeutic in most occasions while they could be proarrhythmic in specific occasions. For instance, Apamin, a selective SK channel blocker, is proved to have antiarrhythmic effects including AP maintenance and calcium homeostasis regulation.89 However, it is proved to be proarrhythmic in hypokalaemic hearts of HFD mice by prolonging APD and generating calcium alternans.90 Recent basic researches have indicated that antiarrhythmic therapy may not solely rely on conventional drugs. Gene and biomaterial therapies have shown great potential in antiarrhythmic therapy.91,92,93 Future antiarrhythmic may be more personalized, visualized and precise. Historically, electrocardiography and electro-anatomical mapping underwent extensive foundational research prior to their widespread adoption in clinical diagnostics and therapeutics. Currently, optical mapping appears to be undergoing a similar trajectory. With continued scientific and technological progress and combination with emerging techniques, such as optoacoustic imaging, all-optical electrophysiology, 4D mapping combined with ultrasound and transparent ultrasound transducer,27,94,95 it is anticipated that comprehensive, in vivo optical mapping and optogenetic methodologies will become increasingly integrated into clinical practice. Acknowledgments This work was supported by the National Natural Science Foundation of China, China (no. 82570383 to X.O., 82470323 to X.T., and 82270334 to X.T.); Sichuan Science and Technology Program, China (no. 2025ZNSFSC0052 to X.T., 24ZDYF0766 to X.O., 2024JDHJ0051 to X.T., and 2025HJPJ0005 to M.L.); Sichuan Education Department Project, China (17ZA0434 to X.O.); Luzhou Science and Technology Bureau, China (2023RCX174 to X.O., LY-63 to X.O., and 2024LZXNYDJ006 to X.T.). Author contributions X.O. designed the research and revised the manuscript. Y.L., Y.Z., R.D., M.L., T.L., J.L., and R.Z., wrote the manuscript. T.C. and X.T. provided advice on paper writing. X.O., G.H., and X.T. revised the manuscript. All authors contributed to editorial changes in the manuscript. Declaration of interests The authors declare no competing interests. Footnotes Supplemental information can be found online at https://doi.org/10.1016/j.isci.2026.116126. Contributor Information Xiaoqiu Tan, Email: tanxiaoqiu@swmu.edu.cn. Guoliang Hao, Email: guoliang.hao@epscopelab.com. Xianhong Ou, Email: oxh8081@swmu.edu.cn. Supplemental information Data S1. Details of drug classification References Associated Data Supplementary Materials Data S1. Details of drug classification